Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.16
MNKD's Cash to Debt is ranked lower than
94% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. MNKD: 0.16 )
Ranked among companies with meaningful Cash to Debt only.
MNKD' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.33 Max: No Debt
Current: 0.16
Equity to Asset -2.48
MNKD's Equity to Asset is ranked lower than
98% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. MNKD: -2.48 )
Ranked among companies with meaningful Equity to Asset only.
MNKD' s Equity to Asset Range Over the Past 10 Years
Min: -2.48  Med: -0.58 Max: 0.87
Current: -2.48
-2.48
0.87
F-Score: 3
Z-Score: -45.61
M-Score: 4127.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -119.35
MNKD's Operating margin (%) is ranked lower than
55% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. MNKD: -119.35 )
Ranked among companies with meaningful Operating margin (%) only.
MNKD' s Operating margin (%) Range Over the Past 10 Years
Min: -3073570  Med: -350481.86 Max: -119.35
Current: -119.35
-3073570
-119.35
Net-margin (%) -126.47
MNKD's Net-margin (%) is ranked lower than
56% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. MNKD: -126.47 )
Ranked among companies with meaningful Net-margin (%) only.
MNKD' s Net-margin (%) Range Over the Past 10 Years
Min: -2931900  Med: -402755.43 Max: -126.47
Current: -126.47
-2931900
-126.47
ROA (%) -140.01
MNKD's ROA (%) is ranked lower than
91% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. MNKD: -140.01 )
Ranked among companies with meaningful ROA (%) only.
MNKD' s ROA (%) Range Over the Past 10 Years
Min: -141.48  Med: -70.42 Max: -54.14
Current: -140.01
-141.48
-54.14
ROC (Joel Greenblatt) (%) -243.87
MNKD's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. MNKD: -243.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MNKD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -285.89  Med: -96.5 Max: -70.3
Current: -243.87
-285.89
-70.3
EBITDA Growth (3Y)(%) 3.30
MNKD's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. MNKD: 3.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MNKD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -43  Med: -25.4 Max: 10.9
Current: 3.3
-43
10.9
EPS Growth (3Y)(%) -1.10
MNKD's EPS Growth (3Y)(%) is ranked higher than
54% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. MNKD: -1.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MNKD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -42.9  Med: -22.9 Max: 7.6
Current: -1.1
-42.9
7.6
» MNKD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

MNKD Guru Trades in Q4 2015

Paul Tudor Jones 219,364 sh (+399.44%)
Murray Stahl 380,440 sh (+74.55%)
» More
Q1 2016

MNKD Guru Trades in Q1 2016

Murray Stahl Sold Out
Paul Tudor Jones 103,372 sh (-52.88%)
» More
Q2 2016

MNKD Guru Trades in Q2 2016

Paul Tudor Jones 103,325 sh (-0.05%)
» More
Q3 2016

MNKD Guru Trades in Q3 2016

Paul Tudor Jones 103,325 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MNKD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ESPR, NAS:STML, NAS:CARA, NAS:IDRA, NAS:SGMO, NYSE:KDMN, NAS:MNOV, NAS:RXDX, NAS:ABEO, OTCPK:CLVLF, NAS:ARWR, NAS:CMRX, NAS:PETX, NAS:OCUL, NAS:MRUS, NAS:PTI, AMEX:PFNX, NAS:PRTK, OTCPK:SPHDF, AMEX:AST » details
Traded in other countries:NNF1.Germany,
MannKind Corp is a development stage company engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes.

MannKind Corp a development stage biopharmaceutical company, was incorporated in the state of Delaware on February 14, 1991. The Company is engaged in the discovery, development and commercialization of therapeutic products for diseases such as diabetes. Its product candidate, AFREZZA inhalation powder, is an ultra rapid-acting insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Its other product MKC253, MKC253 is a Technosphere formulation of GLP-1. Results from a phase 1 trial supported the hypothesis that inhalation of MKC253 may be able to simulate the incretin effect that is lost in patients with type 2 diabetes. Products manufactured in the United States and marketed outside the United States are subject to certain FDA regulations, as well as regulation by the country in which the products are to be sold.

Ratios

vs
industry
vs
history
P/S 2.22
MNKD's P/S is ranked higher than
89% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. MNKD: 2.22 )
Ranked among companies with meaningful P/S only.
MNKD' s P/S Range Over the Past 10 Years
Min: 1.28  Med: 3985 Max: 10655
Current: 2.22
1.28
10655
Current Ratio 0.46
MNKD's Current Ratio is ranked lower than
94% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. MNKD: 0.46 )
Ranked among companies with meaningful Current Ratio only.
MNKD' s Current Ratio Range Over the Past 10 Years
Min: 0.12  Med: 1.32 Max: 12.24
Current: 0.46
0.12
12.24
Quick Ratio 0.41
MNKD's Quick Ratio is ranked lower than
94% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. MNKD: 0.41 )
Ranked among companies with meaningful Quick Ratio only.
MNKD' s Quick Ratio Range Over the Past 10 Years
Min: 0.12  Med: 1.32 Max: 12.24
Current: 0.41
0.12
12.24
Days Inventory 201.28
MNKD's Days Inventory is ranked lower than
70% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. MNKD: 201.28 )
Ranked among companies with meaningful Days Inventory only.
MNKD' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 201.28
Current: 201.28
0
201.28
Days Sales Outstanding 7.05
MNKD's Days Sales Outstanding is ranked higher than
89% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. MNKD: 7.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNKD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.05  Med: 8825.7 Max: 30331.5
Current: 7.05
7.05
30331.5
Days Payable 163.28
MNKD's Days Payable is ranked higher than
80% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. MNKD: 163.28 )
Ranked among companies with meaningful Days Payable only.
MNKD' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 163.28
Current: 163.28
0
163.28

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -14.40
MNKD's 3-Year Average Share Buyback Ratio is ranked lower than
59% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. MNKD: -14.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNKD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58.3  Med: -42.5 Max: -8
Current: -14.4
-58.3
-8

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -34.90
MNKD's Earnings Yield (Greenblatt) (%) is ranked lower than
83% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. MNKD: -34.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MNKD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -41.8  Med: 157.5 Max: 7504.7
Current: -34.9
-41.8
7504.7

More Statistics

Revenue (TTM) (Mil) $162.4
EPS (TTM) $ -0.55
Beta2.76
Short Percentage of Float38.29%
52-Week Range $0.41 - 2.24
Shares Outstanding (Mil)478.38

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) -0.17 -0.15 -0.16
EPS w/o NRI ($) -0.17 -0.15 -0.16
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for MNKD

Headlines

Articles On GuruFocus.com
Searching for Value in the REIT Rubble Dec 09 2016 
UCB's Vimpat Patent Dec 09 2016 
The Only Rule Is It Has to Work Dec 09 2016 
David Winters' Sole Third-Quarter Pick Is Israeli Defense Company Dec 09 2016 
Abbott Laboratories Announces Quarterly Dividend Dec 09 2016 
Steven Cohen Hikes Bunge Holding by Nearly 1,500% Dec 09 2016 
A 3.5% Dividend Yield and Emerging Market Growth Dec 09 2016 
Hershey Has a Sweet Dividend, but Valuation Could Be Too Rich Dec 09 2016 
4 Gurus Invest in Hilton Worldwide Dec 09 2016 
Bill Ackman Comments on Herbalife Dec 09 2016 

More From Other Websites
Theravance Stock Up on Fast Track Status for Velusetrag Dec 07 2016
MANNKIND CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets Dec 07 2016
MannKind (MNKD): Strong Industry, Solid Earnings Estimate Revisions Dec 01 2016
Short Sellers Grow More Aggressive on Major Biotechs Nov 28 2016
10 Most Shorted Nasdaq Stocks Nov 28 2016
MANNKIND CORP Financials Nov 17 2016
A Trump Victory Sparks Stock Market Surge Nov 14 2016
MANNKIND CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 14 2016
Sanofi Gets Hosed on MannKind Deal (SNY, MNKD) Nov 11 2016
Edited Transcript of MNKD earnings conference call or presentation 9-Nov-16 10:00pm GMT Nov 11 2016
Mannkind (MNKD) Q3 Earnings Beat, Inks Deal with Sanofi Nov 10 2016
MannKind Is Still Too Heavy to Avoid the Afrezza Crash Landing Nov 10 2016
Short Sellers Grow More Selective on Major Biotechs Nov 10 2016
The 6 Most Shorted Nasdaq Stocks Nov 10 2016
MannKind and Sanofi Reach Agreement on AFREZZA® Nov 09 2016
MannKind, Sanofi Reach Agreement on AFREZZA; Sanofi to Purchase $10.2M Worth of Insulin from... Nov 09 2016
MannKind and Sanofi Reach Agreement on AFREZZA® Nov 09 2016
MannKind posts 3Q profit Nov 09 2016
MannKind Corporation Reports 2016 Third Quarter Financial Results Nov 09 2016
MannKind Corporation to Hold 2016 Third Quarter Financial Results Conference Call on November 9,... Nov 01 2016
Securities Class Action Against MannKind Dismissed Aug 25 2016
MannKind reports 2Q loss Aug 09 2016
MannKind Corporation Reports 2016 Second Quarter Financial Results Aug 08 2016
MannKind Corporation to Hold 2016 Second Quarter Financial Results Conference Call on August 8, 2016 Aug 01 2016
Mannkind Assumes Responsibility for Distribution of Afrezza® and Launches Patient Reimbursement and... Aug 01 2016
MannKind Corporation to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference Jul 08 2016
MannKind Announces Late-Breaking Data Reinforcing Faster Onset and Shorter Duration of Action... Jun 12 2016
MannKind Announces Collaboration with JDRF Jun 10 2016
MannKind Announces Pricing of Registered Direct Public Offering of Common Stock and Warrants May 09 2016
MannKind reports 1Q loss May 09 2016
MannKind Corporation Reports 2016 First Quarter Financial Results May 09 2016
MannKind Corporation to Present at the Bank of America Merrill Lynch 2016 Health Care Conference May 05 2016
MannKind Corporation to Hold 2016 First Quarter Financial Results Conference Call on May 9, 2016 May 02 2016
Analyst Call Rescheduled to April 26, 2016 Apr 19 2016
MannKind Expands Commercial Capabilities With Two New Hires Apr 19 2016
MannKind Regains Afrezza® Marketing Rights Apr 05 2016
MannKind reports 4Q loss Mar 14 2016
MannKind Corporation to Hold Investor Conference Call on February 3, 2016 Jan 27 2016
MannKind Enters Into Collaboration and License Agreement Jan 21 2016
MannKind Provides Update on Senior Management Jan 11 2016
MannKind reports 3Q loss Nov 09 2015
MannKind reports 2Q loss Aug 10 2015
MannKind slumps after Sanofi details Afrezza sales Jul 30 2015
MannKind reports 4Q loss Feb 24 2015
MannKind reports 3Q loss Nov 03 2014
MannKind, Sanofi enter Afrezza deal worth $925M Aug 11 2014
Sanofi bets on inhaled insulin with MannKind deal Aug 11 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)